Orphan Drugs: Understanding the Rare Disease Market and its Dynamics
- ISBN-10
- 1908818395
- ISBN-13
- 9781908818393
- Series
- Orphan Drugs
- Category
- Medical
- Pages
- 334
- Language
- English
- Published
- 2013-11-15
- Publisher
- Elsevier
- Authors
- Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Description
This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups. The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey. After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs. The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs. A comprehensive overview of strategy, key activities and considerations of how to bring an orphan drug from concept to the market and make it available to patients A source of updated information, news and trends for those who are already active in this fast-evolving field Covers the global definitions and the criteria for getting an orphan drug designation in, for example, the US and Europe
Get the book
Other editions
-
- 2018-11-13
- 334 pages
- Paperback
- Woodhead Publishing
-
- 2016-12-15
- 320 pages
- Paperback
- CRC Press
-
- 1983
- 12 pages
- Paperback
- Vance Bibliographies
Similar books
-
Orphan Drugs and Rare Diseases
By David C Pryde, Michael J PalmerThis book provides an up-to-date monograph on the drug discovery and regulatory elements of therapeutics used to treat rare or "orphan" diseases.
-
Orphan Diseases and Orphan Drugs
By I. Herbert Scheinberg, J. M. WalsheOrphan Diseases and Orphan Drugs
-
Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases
By Jules J. BermanOften, the disease process manifested in a certain rare disease is strikingly similar to the disease process observed in a common disease. This work ties the lessons learned about rare diseases to our understanding of common ones.
-
Rare Diseases and Orphan Products: Accelerating Research and Development
By Institute of Medicine, Board on Health Sciences Policy, Committee on Accelerating Rare Diseases Research and Orphan Product DevelopmentRare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging.
-
Searching for Magic Bullets: Orphan Drugs, Consumer Activism, and Pharmaceutical Development
By Lisa A Basara, Michael E MontagneAccording to Sidney Wolfe , a physician and well - known consumer advocate , the prevalence of doctor - bribing and acquisition of bogus clinical data through large pay - offs is higher than most people believe . Wolfe described several ...
-
Orphan Drug Reauthorization: Hearing Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House...
By United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the EnvironmentOrphan Drug Reauthorization: Hearing Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House...
-
Orphan Drugs in Epilepsy
By M. Nikanorova, P. Genton, S. I. Johannessen- There are few drugs available. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies. Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc.
-
Exclusion of Orphan Drugs for Certain Covered Entities Under 340b Program (Us Health Resources and Services Administration Regulation) (Hrsa) (2018...
By The Law The Law LibraryThis book contains: - The complete text of the Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program (US Health Resources and Services Administration Regulation) (HRSA) (2018 Edition) - A table of contents with the page ...
-
Evergreening Patent Exclusivity in Pharmaceutical Products: Supplementary Protection Certificates, Orphan Drugs, Paediatric Extensions and ATMPs
By Frantzeska PapadopoulouThis book analyses 4 central pieces of EU pharmaceutical regulation: the Orphan Drugs Regulation, the Paediatric Regulation, the Supplementary Protection Certificate Regulation, and the ATMP (Advanced Therapy Medicinal Products) Regulation.
-
Orphan Drugs
By Fred KarchOrphan Drugs